PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) will meet with investors at four healthcare conferences in September, putting its late-stage autoimmune cell therapy program before the market as the Philadelphia biotechnology company advances its lead candidate, rese-cel.
The company is scheduled for investor meetings Sept. 8 at the Wells Fargo 21st Annual Healthcare Conference in Boston, followed by appearances at three New York conferences through Sept. 16.
Cabaletta will hold a webcasted fireside chat at 8:35 a.m. ET Sept. 9 during the 2026 Cantor Global Healthcare Conference and another at 10:45 a.m. ET Sept. 14 at the Morgan Stanley 24th Annual Global Healthcare Conference.
It is also scheduled for a fireside chat at 8:30 a.m. ET Sept. 16 at the H.C. Wainwright 28th Annual Global Investment Conference.
The conference schedule gives Cabaletta several investor-facing opportunities as it develops rese-cel, an investigational CD19 CAR-T cell therapy for autoimmune diseases.
Rese-cel is being studied through the company’s RESET clinical development program across rheumatology, neurology and dermatology. The therapy incorporates a 4-1BB signaling domain and is designed to target CD19-expressing B cells.
Cabaletta did not specify whether it plans to present new clinical or financial data at the conferences.
Webcasts of the Cantor and Morgan Stanley fireside chats will be available through the News and Events section of the company’s website at www.cabalettabio.com. Archived replays will remain available for 30 days.
Cabaletta Bio is headquartered in Philadelphia, where it also operates laboratory facilities.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.